Amerimmune Allergy Testing:

Seeking FDA Approval for Peanut Allergy Testing

Our mission is to commercialize the first FDA-Cleared 'Virtual' Peanut Allergy Test

  • Basophil Activation Testing (BAT) amounts to a "Virtual Food Challenge", i.e. no more eating peanuts in a clinical setting.

  • Amerimmune's BAT represents the first significant allergy test innovation in 150 years and a patent filed with U.S. Patent Office on 04/01/2022.

  • Est. 6.1 million Americans suffer from peanut allergies.

  • Global Allergy Diagnostics Market is projected to reach $8.2 billion by 2026, with peanut allergy projected to grow at 21.9% per year through 2030.

 
 

Big Pharma Investing Heavily in the Peanut | Food Allergy Market

~ Today 10 other pharmaceutical organizations are developing peanut allergy treatments, including Sanofi, Genentech (Roche), and Novartis.

~ In August 2020, Nestle Health Sciences, acquired the maker of the first FDA-approved children’s peanut allergy treatment, Aimmune Therapeutics, for $2.6 billion.

 

Peanut allergy is one of the most common food allergies and, in the majority of individuals, it begins early in life and persists throughout life.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has developed clinical recommendations to prevent the development of peanut allergy.

FDA Completes Review of a Notification Regarding a Health Claim Related to Peanut Allergies 12/8/21